Actelion Ltd. Profile, SWOT Analysis and Company Tech Intelligence Report 2018

Report Name: Actelion Ltd.  Profile – Overview, History, SWOT Analysis, Products/Services, Facts, Financials, Key Executives, Competitors, Tech Intelligence, IT Outsourcing, IT Management, Recent Developments and Strategy Evaluation

ACTELION LTD.  Report – Publisher: Research Cosmos

Price Scheme of the Report:

Single User License – USD 150

Team License – USD 175

Corporate License – USD 250

ACTELION LTD.  – Business Description:

Actelion Ltd. is engaged in the discovery, development and commercialization of drugs for the treatment of diseases across various therapeutic areas including cardiovascular disorders, central nervous system disorders, infectious diseases, cancer, and immunological disorders. It has operations in more than 30 countries in North and South America, Europe and Asia Pacific.

The company operates in one segment, which primarily focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. However, the company derives majority of its revenues from the sales of its seven products: Tracleer (bosentan), Opsumit (macitentan), Uptravi (selexipag), Zavesca (miglustat), Veletri (epoprostenol for injection), Ventavis (iloprost), and Valchlor (mechlorethamine).

Tracleer is an oral endothelin receptor antagonist used for the treatment of pulmonary arterial hypertension (PAH). The company currently markets Tracleer in over 60 markets, including the US, the European Union (EU), and Japan. In FY2016, Tracleer recorded sales of CHF1,020 million, which accounted for 42.3% of the company’s total product sales.

Opsumit is used for the treatment of PAH (WHO Group I) to delay disease progression. Opsumit is commercially available in over 45 markets, including the US, Germany, and Japan. In Europe, it is indicated, as monotherapy or in combination, for the long-term treatment of PAH in adult patients of WHO Functional Class (FC) II to III. In FY2016, Opsumit recorded sales of CHF831 million, which accounted for 34.4% of the company’s total product sales.

Uptravi is an oral selective IP receptor agonist targeting the prostacyclin pathway in PAH. In the US, it is indicated for the treatment of PAH (WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH where as in Europe, Uptravi is indicated for the long-term treatment of PAH in adult patients with WHO FC II-III. Uptravi is available in 9 countries, including the US and Germany. It has received market authorization in Australia, Canada, the EU, Japan, New Zealand, South Korea, Switzerland and the US. In FY2016, Uptravi recorded sales of CHF245 million, which accounted for 10.2% of the company’s total product sales.

Zavesca is an orally active competitive, reversible inhibitor of glucosylceramide synthase. In the US, it is indicated as monotherapy for the treatment of adult patients with mild to moderate type 1 Gaucher disease (GD-1) for whom enzyme replacement therapy is not a therapeutic option. In the EU, Zavesca is also indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C (NP-C) disease. In FY2016, Zavesca recorded sales of CHF104 million, which accounted for 4.3% of the company’s total product sales.

Veletri is indicated for the treatment of PAH (WHO Group 1) to improve exercise capacity. Veletri is available in 17 markets, including the US, Switzerland and Canada (marketed as Caripul), Japan (marketed as Epoprostenol ACT), and some European markets. In FY2016, Veletri recorded sales of CHF97 million, which accounted for 4% of the company’s total product sales.

Ventavis, an inhaled formulation of iloprost, is indicated for the treatment of PAH (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Actelion markets its drug in the US through its subsidiary, CoTherix. In FY2016, Ventavis recorded sales of CHF73 million, which accounted for 3% of the company’s total product sales.

Valchlor is a gel used for skin related treatments. In the US, Valchlor gel is indicated for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy. In FY2016, Valchlor recorded sales of CHF35 million, which accounted for 1.5% of the company’s total product sales.

In addition, the company generated sales of CHF8 million from other products in FY2016, which accounted for 0.3% of its total product sales.

Geographically, the company classifies its operations into five segments, namely the US, Japan, Switzerland, EU-28, and other countries. In FY2016, the US segment accounted for 54.1% of the company’s total product sales, followed by Japan with 10.7%; Switzerland with 1.1%; EU-28 countries with 25.7%; and other countries with 8.4%.

Scope of the Report:

About the Company: Historical Details, Current Ownership Structure and basic overview of Balfour Beatty plcin terms of revenue, net income, and operating income.

Financials: Details about Balfour Beatty plclisting status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.

Products/Services: Listing of the company’s entire portfolio along with the description of individual products/services providing a clear picture of their target audience.

Company SWOT Analysis: Outlines Atea ASA.’s strengths, weaknesses, and opportunities and threats facing the company.

Recent Developments: Showcases Atea ASA.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.

Strategic Evaluation: This section provides an overview of Atea ASA.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.

Technology Landscape: Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken by the company at present along with outlook.

Key Questions Answered

What domain does Balfour Beatty plcoperate and what are key points about it?

What is the product/service portfolio of Atea ASA.?

How has Balfour Beatty plcperformed financially from 2013?

How does Balfour Beatty plcrank among its peers in terms of revenue and market share?

What are Balfour Beatty plcstrengths and weaknesses and what opportunities and threats do it face?

What are Atea ASA.’s main growth strategies and how successful has the company been at implementing them?

What is the in-house technical capability of Atea ASA.? Where does it procure/outsource it?

Reasons to buy

Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own

Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at a very competitive cost

12 hour delivery time fulfilling your urgent requests as per your requirement

On-demand customization options that can completely cater to your needs by focusing the report on given specifics

For More Information, Get Sample of the report:Request Sample

Got Some Questions? Inquire Here:Inquire Before Buying

Get This Report:Purchase Now

For More Details, Contact Provider Directly:

Kevin Stewart
Sales Manager
Research Cosmos
+1 888 709 8757

Be the first to comment

Leave a Reply